How will the market of antibacterial drugs develop with the continuous upgrading of "anti restriction order"

[policies and regulations of China Pharmaceutical network] on March 29, in order to continuously strengthen the management of clinical application of antibiotics, ensure the quality of medical treatment, and curb bacterial resistance, the national health and Health Commission issued the notice on continuously improving the management of clinical application of antibiotics, and put forward five requirements (photo source: chinapharma.com) to further optimize the management mode of antibacterial drugs On the one hand, we should formulate and implement the technical specifications of antimicrobial management, establish a scientific concept of antimicrobial clinical application management, and make clear the management objectives of improving the outcome of infectious diseases and improving the quality of medical treatment On the other hand, we will promote multidisciplinary diagnosis and treatment of infectious elite soldiers Second, efforts should be made to improve the ability of rational application of antibiotics We should carry out extensive training on antimicrobial knowledge, focus on strengthening the training of doctors, and improve the compliance of diagnosis and treatment norms and clinical routes for infectious diseases We should attach great importance to the construction of related disciplines, and improve the technical support system for the clinical application of antimicrobial drugs by strengthening the construction of disciplines In addition, we need to improve the level of antimicrobial use at the grass-roots level and strengthen technical support for county hospitals and grass-roots medical institutions We should do a good job in the prevention and notification of 100 million yuan of infection, strictly implement the basic measures for prevention and control of hospital infection, improve the health compliance of doctors, and implement the relevant operation specifications and technical standards Third, pay close attention to the key link management of the application of antibiotics We should strengthen the connotation construction of the special file management, continue to implement the special file management of carbapenem antibiotics and tegacyclin according to the clinical monitoring situation, and do a good job in the connotation management It is necessary to reasonably adjust the supply catalogue of antibacterial drugs in consideration of the application of new drugs and technologies We should also reduce the use of prophylaxis and unreasonable intravenous infusion, and change the situation of over dependence on antibiotics to prevent surgical infection Fourth, improve the management level of antibiotics We should rely on information technology and strengthen information management To carry out the stage effect evaluation, we should focus on strengthening the evaluation of the rational use of initial antibiotics in patients with sepsis (including septicemia), septic shock and so on To do a good job in clinical monitoring, all medical institutions shall submit monitoring data to the monitoring network for clinical application of antimicrobial drugs and the monitoring network for bacterial resistance in accordance with the requirements, and ensure the data quality Fifth, we should carry out scientific knowledge popularization, publicity and education, establish a regular publicity mechanism for the rational use of antibacterial drugs, and carry out publicity activities with the World Health Organization in the third week of November every year In response to the notice and related requirements, the industry believes that a lot of signals have been released For example, restrictions on the use of clinical antibiotics will be further tightened, and a large number of antibacterial products will be kicked out of the hospital market Analysts believe: "combined with the requirements of the notice on" reducing the use of prevention and unreasonable intravenous infusion ", large infusion varieties may bear the brunt In addition, a large number of drugs will also be kicked out of the hospital market, such as carbapenem antibiotics and tegacyclin, which were listed in the" restricted list "by the former national health and Family Planning Commission for many times, are very dangerous "It can be seen that in the notice issued this time, the national health and Health Commission has repeatedly mentioned the management of these two kinds of drugs, and at the same time, the enzyme inhibitor compound has also been named." Experts said In addition, intravenous infusion is still the focus of attention With the upgrading of "anti restriction order" and the popularization of the concept of "no intramuscular injection for oral administration, no intramuscular injection for intramuscular injection", the scope of eliminating outpatient infusion will continue to expand At the same time, there is a tendency to expand the scope of outpatient infusion to basic medical institutions In general, under the pressure of "anti drug restriction" and environmental protection, the old big infusion enterprises, such as Kelun pharmaceutical, Shijiazhuang No.4 pharmaceutical, Cr Shuanghe, etc., are seeking transformation.